Sarepta Therapeutics, Inc. or PTC Therapeutics, Inc.: Who Leads in Yearly Revenue?

Biotech Revenue Race: Sarepta vs. PTC from 2014 to 2023

__timestampPTC Therapeutics, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014229630009757000
Thursday, January 1, 2015367660001253000
Friday, January 1, 2016827050005421000
Sunday, January 1, 2017194392000154584000
Monday, January 1, 2018264734000301034000
Tuesday, January 1, 2019306980000380833000
Wednesday, January 1, 2020380766000540099000
Friday, January 1, 2021538593000701887000
Saturday, January 1, 2022698801000933013000
Sunday, January 1, 20239378220001243336000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc. have been neck and neck in their quest for market leadership. Starting in 2014, PTC Therapeutics had a slight edge with revenues nearly double that of Sarepta. However, by 2023, Sarepta surged ahead, boasting a revenue increase of over 12,600% compared to its 2014 figures, while PTC's revenue grew by approximately 4,000%.

This remarkable growth trajectory highlights the dynamic nature of the biotech industry, where innovation and strategic investments can lead to exponential gains. As of 2023, Sarepta's revenue stands at 1.24 billion, outpacing PTC's 937 million. This data not only underscores the fierce competition but also the potential for significant financial rewards in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025